Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCAP-XX Regulatory News (CPX)

Share Price Information for CAP-XX (CPX)

Share Price is delayed by 15 minutes
Get Live Data
0.265    -0.005 (-1.85%)
Bid:
0.25
Ask:
0.28
Spread: 0.03 (12.00%)
Market Cap: £15.36m
CPX Live PriceLast checked at - London Stock Exchange

Intraday CAP-XX Share Chart

Update on IP and appeals process

10 Jan 2024 07:02

RNS Number : 2259Z
CAP-XX Limited
10 January 2024
 

 

Dissemination of a Regulatory Announcement that contains inside information for the purposes of Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310.

 

10 January 2024

CAP-XX Limited

("CAP-XX" or the "Company")

Update on IP and appeals process

 

Further to the Company's announcement on 21 December 2023, CAP-XX Limited, a world leader in the design and manufacture of supercapacitors and energy management systems, provides the following update.

On 27 December 2023, the Delaware District Court entered judgment in favour of Maxwell Technologies in a patent infringement case asserted by CAP-XX. While CAP-XX is disappointed with the result, it is evaluating all options, including making an appeal to the Federal Circuit Court of Appeals.

CAP-XX has subsequently conducted a review of its patent portfolio and concluded that the Delaware District Court judgment does not have any impact on the integrity of the Company's portfolio of current patents and IP, the integrity and enforceability of its current licensing deals not the subject of this case, or the integrity of its portfolio of current patents awarded or pending. Furthermore, under US law there is no valid grounds for clawback if a licensed or expired patent is later invalidated.

The patents that were made invalid in the Delaware judgement were US 6,920,034 and US 7,382,600. Both of these patents expired in December 2019. The case took more than five years to be heard and the initial notification by CAP-XX to Maxwell (subsequently acquired by Tesla) for patent infringement was first made in September 2017.

CAP-XX's portfolio of current active patents comprises:

· US7,595,131

· US7,474,879

· US7,969,121

· US8,773,841

In addition, CAP-XX has two international patent applications that relate to:

· new binders PCT/AU2023/015252

· a new supercapacitor surface mount device (SMD) PCT/AU2023/051251

 

The Directors of CAP-XX believe that the Delaware District Court judgment will not have a materially adverse effect on CAP-XX's ongoing business, which remains in line with the update provided on 21 December 2023.

As previously reported, the Company looks forward to proceeding with its current product range, supported by a strong portfolio of current IP, to focus on the key short-term actions to maximise sales and deliver profitability.

 

 

 

 

For further information contact:

CAP-XX Limited

Pat Elliott (Chairman) +61 (2) 9157 0000

Lars Stegmann (Chief Executive Officer)

 

Allenby Capital (Nominated Adviser and Joint Broker)

David Hart / Piers Shimwell (Corporate Finance)  +44 (0) 20 3328 5656

Tony Quirke / Stefano Aquilino (Sales and Corporate Broking)

 

Cavendish Securities plc (Joint Broker)

Neil McDonald / Pearl Kellie +44 (0) 13 1220 6939

 

Kreab (Financial PR)

Robert Speed +44 (0) 20 7074 1800

 

 

Notes to Editors:

CAP-XX (LSE: CPX) is a leader in the design and manufacture of thin, flat supercapacitors and energy management systems used in portable and small-scale electronic devices, and to an increasing extent, in larger applications such as automotive and renewable energy. The unique feature of CAP-XX supercapacitors is their very high power density and high energy storage capacity in a space-efficient prismatic package. These attributes are essential in power-hungry consumer and industrial electronics, and deliver similar benefits in automotive and other transportation applications. For more information about CAP-XX, visit www.cap-xx.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDGRGDBBGBDGSG
Date   Source Headline
2nd Feb 20267:00 amRNSInterim Results
23rd Jan 20267:00 amRNSNotice of Interim Results & Investor Presentation
19th Dec 202510:13 amRNSReceipt of R&D tax credit
19th Dec 202510:13 amRNSReceipt of R&D tax credit
10th Dec 20252:16 pmRNSHolding(s) in Company
28th Nov 20255:00 pmRNSTotal Voting Rights
28th Nov 202510:13 amRNSResult of AGM
14th Nov 20257:00 amRNSIssue of Shares and Director/PDMR Shareholding
10th Nov 20257:00 amRNSDirector/PDMR Shareholding
7th Nov 20257:00 amRNSFinal results and notice of AGM
30th Oct 20251:02 pmRNSHolding(s) in Company
17th Sep 20257:00 amRNSHolding(s) in Company
16th Sep 20257:00 amRNSImplementation of Warehouse Management System
10th Sep 202511:48 amRNSHolding(s) in Company
7th Aug 20257:00 amRNSHolding(s) in Company
5th Aug 20257:00 amRNS-RDesign Win with Global Semiconductor Manufacturer
31st Jul 20255:00 pmRNSTotal Voting Rights
25th Jul 20257:00 amRNSHolding(s) in Company
18th Jul 20257:00 amRNSUpdate re. collaboration with SCHURTER
2nd Jul 20257:00 amRNSHolding(s) in Company
1st Jul 20257:29 amRNSIssue of Shares and Director/PDMR Shareholdings
30th Jun 20257:00 amRNSGlobal Distribution Agreement with RS Group plc
9th Jun 20257:00 amRNSBusiness Update and Appointment of Interim CFO
30th May 202510:32 amRNS-RUpdated website
13th May 202511:31 amRNS-RDesign Win with Multinational Conglomerate
30th Apr 20251:57 pmRNSChange of Auditor
26th Mar 20257:00 amRNSGrant of share options
19th Mar 20257:00 amRNSChange of Board Structure and Grant of Options
18th Mar 20259:35 amRNSGlobal Distribution Agreement with Premier Farnell
12th Mar 20252:43 pmRNSTechnology Cooperation Agreement with SCHURTER
7th Mar 20257:00 amRNSMaster Distribution Agreement with Waldom
17th Feb 20257:00 amRNSHalf-year Results
11th Feb 20257:00 amRNSNotice of Interim Results & Investor Presentation
31st Jan 20255:00 pmRNSTotal Voting Rights
21st Jan 20254:27 pmRNSIssue of Shares and Director/PDMR Shareholding
20th Jan 20257:00 amRNSUpdate re. R&D Tax Credit
20th Jan 20257:00 amRNSUpdate re. R&D Tax Credit
17th Jan 20257:00 amRNS-RDistribution agreement with JM Elektronik
15th Jan 20257:00 amRNSFirst shipment to SCHURTER AG
13th Jan 202511:29 amRNSResult of AGM
7th Jan 20257:00 amRNSManagement and board changes
31st Dec 20241:00 pmRNSTotal Voting Rights
9th Dec 202410:19 amRNSNotice of AGM
5th Dec 20248:18 amRNSResult of General Meeting
29th Nov 20245:00 pmRNSTotal Voting Rights
29th Nov 20249:57 amRNSDirectors' Subscription
29th Nov 20247:00 amRNSAudited results for the year ended 30 June 2024
5th Nov 20247:00 amRNSResult of Retail Offer, Notice of GM and TVR
1st Nov 20247:00 amRNSResult of Placing
31st Oct 20244:40 pmRNSRetailBook Offer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.